Valeo Pharma Inc. (VPH.TO)
| Previous Close | 0.0950 |
| Open | 0.0950 |
| Bid | 0.1050 x N/A |
| Ask | 0.1150 x N/A |
| Day's Range | 0.0950 - 0.1150 |
| 52 Week Range | 0.0600 - 0.5200 |
| Volume | |
| Avg. Volume | 64,008 |
| Market Cap | 11.346M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings Date | Jun 11, 2024 - Jun 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.50 |
CNW GroupVALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting").
CNW GroupVALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Steve Saviuk, Valeo's Chief Executive Officer, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
- Baystreet
Stocks in play: Valeo Pharma Inc.
Announced that Al Moghaddam has joined the Company's Board of Directors. Valeo Pharma Inc. shares T.VPH ...
